Concord Medical prices IPO near top, but falls on debut

The operator of cancer treatment centres avoids the fate of two other Chinese listing candidates which were forced to re-price or pull their US IPOs, but the stock still slumps 13.6% on the first day of trading.

To continue reading, please login or register for free

Print Edition

FinanceAsia Print Edition